14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends
Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use
of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in …
of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in …
Antiphospholipid antibody testing and standardization
KMJ Devreese - International journal of laboratory hematology, 2014 - Wiley Online Library
The laboratory criteria that define patients with antiphospholipid syndrome (APS) include
lupus anticoagulant (LAC), anticardiolipin antibodies and anti‐β2 glycoprotein I antibodies …
lupus anticoagulant (LAC), anticardiolipin antibodies and anti‐β2 glycoprotein I antibodies …
A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome
C Agostinis, P Durigutto, D Sblattero… - Blood, The Journal …, 2014 - ashpublications.org
A single-chain fragment variable (scFv) recognizing β2-glycoprotein 1 (β2GPI) from humans
and other species was isolated from a human phage display library and engineered to …
and other species was isolated from a human phage display library and engineered to …
[图书][B] Recurrent pregnancy loss: causes, controversies, and treatment
HJA Carp - 2014 - books.google.com
Recurrent pregnancy loss presents a vexing clinical problem primarily for medical
professionals treating patients in reproductive medicine and in maternal-fetal medicine …
professionals treating patients in reproductive medicine and in maternal-fetal medicine …
New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies
CB Chighizola, M Gerosa, PL Meroni - Current rheumatology reports, 2014 - Springer
Abstract Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid
antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) …
antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) …
Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage
Antiphospholipid syndrome (APS) is a multiorgan disease often affecting the central nervous
system (CNS). Typically, neurological manifestations of APS include thrombosis of cerebral …
system (CNS). Typically, neurological manifestations of APS include thrombosis of cerebral …
The chequered history of the antiphospholipid syndrome
D Jayakody Arachchillage… - British journal of …, 2014 - Wiley Online Library
Consideration of the chronology of advances in medical knowledge can provide useful
insights into the pathogenesis, diagnosis and treatment of diseases. The antiphospholipid …
insights into the pathogenesis, diagnosis and treatment of diseases. The antiphospholipid …
Laboratory methods to detect antiphospholipid antibodies
SA Krilis, B Giannakopoulos - Hematology 2014, the American …, 2014 - ashpublications.org
This chapter reviews several important themes pertaining to the antiphospholipid syndrome
(APS), including a description of the clinical features, a discussion of the main autoantigen …
(APS), including a description of the clinical features, a discussion of the main autoantigen …
Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and …
L Despierres, A Beziane, G Kaplanski, B Granel… - …, 2014 - academic.oup.com
Objectives. Although the last international guidelines for aPL recommended determination of
IgA aCL and anti-β2glycoprotein I (aβ2GPI) antibodies for the evaluation of APS in the …
IgA aCL and anti-β2glycoprotein I (aβ2GPI) antibodies for the evaluation of APS in the …
Thrombotic risk in the antiphospholipid syndrome
W Lim - Seminars in thrombosis and hemostasis, 2014 - thieme-connect.com
The antiphospholipid syndrome (APS) is characterized by venous or arterial thrombosis
and/or pregnancy morbidity in patients with persistent presence of antiphospholipid …
and/or pregnancy morbidity in patients with persistent presence of antiphospholipid …